Inactive Instrument

International Stem Cell Corp Stock OTC Bulletin Board

Equities

ISCO

US4603781026

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for International Stem Cell Corp
Sales 2022 8.18M Sales 2023 7.79M Capitalization 496K
Net income 2022 - Net income 2023 - EV / Sales 2022 0.61 x
Net Debt 2022 3.53M Net Debt 2023 2.59M EV / Sales 2023 0.4 x
P/E ratio 2022
-4.35 x
P/E ratio 2023
-3.79 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 27.91%
More Fundamentals * Assessed data
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agrees to Extend (Until September 15, 2024) the Maturity Date of the Loan CI
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial RE
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Bayer claims early lead in Parkinson's stem cell therapy RE
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Earnings Flash (ISCO) INTERNATIONAL STEM CELL CORPORATION Reports Q4 Loss $-0.11 MT
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt CI
More news
Managers TitleAgeSince
Chief Executive Officer 64 08-11-30
Director of Finance/CFO 38 08-09-30
Members of the board TitleAgeSince
Director of Finance/CFO 38 08-09-30
Director/Board Member 76 07-06-30
Chief Executive Officer 64 08-11-30
More insiders
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
More about the company